Merck & Co Inc  (MRK) Trade Now »     Rate MRK  -  Discuss MRK  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

MRK: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA Calendar Updates: Anadys, Merck, Schering-Plough MRK

73%

+8.85% in 103 days Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 289 entries as of 7/30/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial results. ... Continue reading »

FDA Calendar, Extreme Trade Updates: CXM, ELRN, SGP, Shire MRK

73%

+0.34% in 2 days (closed on 07/30/09) <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 284 entries as of 7/28/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical... Continue reading »

Merck & Co. Inc. MRK

62%

-9.19% in 508 days BusinessWeek Rankings World's Most Innovative Companies 2007   #46 Best Places to Launch a Career 2007   #49 <> 2006   #18 Merck & Co., Inc. provides various products for human and animal health in the United States and internationally. The company’s Pharmaceutical segment includes human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vaso< /><><><><><><>< /><><><><><><><><><><>< /><><><><><><><><><><><><><><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><>< /><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />< />< /><><><><><><><><><><>< /><><><><>< /><><><><>< /><><><><>< /><><><><>< />< />... Continue reading »

FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP MRK

73%

+1.32% in 6 days (closed on 07/28/09) <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 273 entries as of 7/22/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin... Continue reading »

Updated FDA, Clinical Trial Calendars: CRME, MRK, LLY, PRX MRK

73%

+11.98% in 103 days (closed on 07/22/09) Below is a summary of updates to the BioMedReports.com database of 242 entries included in the FDA and Clinical Trial Calendars .   http://biomedreports.com/fda-calendar.html   <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/9/09. The FDA Calendar includes the following information: company name, ticker, decision ... Continue reading »

From the Blogosphere

Big Pharma and Biotech – Industry Outlook

38%

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co... Continue reading »

Santarus Reports Strong Quarter – Analyst Blog

38%

Santarus, Inc. (SNTS) reported third-quarter earnings of 9 cents per share, surpassing the Zacks Consensus Estimate at a loss of 1 cent and the year-ago loss of 8 cents. Total revenues, consisting of net product sales, promotion revenues, and license and royalty revenues, came in at $39.5 million, up 22% from the year-ago period.<>Product-related revenues, which consist of net product sales and promotion revenues, increased 30% to $38.3 million in the third quarter of 2009. Zegerid net product sales were $31.5 million, up 12%. Total prescriptions increased 6.3% in the reported quarter. Compe... Continue reading »

DJIA Market Wrap 8 November

N/A

The 60-minute trend is positive according to the force index indicator. %b has printed a slightly negative divergence. On Monday morning prices will open up on a gap that will test previous high. The Dow is also doing much better than the Nasdaq in this phase. Most of the stocks are moving above their 20-day moving averages and the trend is very good in the longer term moving averages. HPQ, MCD, PG printed new 20-day highs. MCD has printed 5 and IBM has printed 4 consecutive up closes. I remain negative on the market and will need to assess how high this move will continue. I am opening s... Continue reading »

DJIA Market Wrap 8 November

The 60-minute trend is positive according to the force index indicator. %b has printed a slightly negative divergence. On Monday morning prices will open up on a gap that will test previous high. The Dow is also doing much better than the Nasdaq in this phase. Most of the stocks are moving above their 20-day moving averages and the trend is very good in the longer term moving averages. HPQ, MCD, PG printed new 20-day highs. MCD has printed 5 and IBM has printed 4 consecutive up closes. I remain negative on the market and will need to assess how high this move will continue. I am opening s... Continue reading »

Dividend Portfolio – October 2009 Update

55%

On the first Friday of every month, we will screen our database for the 10 companies with the highest dividend yield that are suitable for the enterprising investor.  These 10 companies will be placed in a mock portfolio and rebalanced to have a 10% allocation to each company.  The starting value of the portfolio is $100,000.00.  Dividends will be reinvested in the portfolio. To see the portfolio, you can view this google spreadsheet. This month’s screen resulted in the following companies being targeted. <> Psychemedics Corp (PMD) – 23.38% B&G Foods Inc (BGS) – 8.45% <><>National Presto Indus... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.